Lucanix for lung cancer

Lucanix is a promising looking vaccine for patients with advanced lung cancer.

It just entered Phase III testing after a successful Phase II testing period where it was thought to nearly double a person’s chance of surviving two years:

The study is designated as the STOP trial because of its expected endpoints: Survival; Tumor-free, Overall; and Progression-free. It is an international, multicenter, randomized, double-blind study involving up to 700 individuals with advanced stage NSCLC, and will be conducted at approximately 90 clinical sites in the U.S., Canada, India, and Europe.

In a Phase II clinical trial, two-year survival among patients with stages IIIB and IV disease who received Lucanix(R) was significantly longer than that of individuals being treated with the current standard of care. A second, investigator-initiated phase II study supported these results.

I’m all for anything that will increase lung cancer survival rates as there are so few things that seem to affect it, we need some good news. I’m very thankful for those men and women who take the time to be in research studies like these (as my mother did) so that it may help future patients.